What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

The new study, published in PLOS ONE, included registry data from nearly 4,500 patients. While COVID-19 patients faced a heightened risk of adverse cardiovascular outcomes early on, many of those risks faded after approximately one month. 

Christine Seidman, MD, director of the cardiovascular genetics program at Brigham & Women’s Hospital, spoke to us about using genetics to crack the code of cardiovascular disease. 

The Kentucky physician fought back against the allegations, but his attorney's arguments were not effective enough to sway the judge. 

Clyde Yancy, MD, vice dean for diversity and inclusion, chief of cardiology, and a professor of medicine in cardiology and medical social sciences at Northwestern Medicine, discusses health equity issues and how greater inclusion should be a business model because of changing demographics.

Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed. 

Even after adjusting for factors such as income, comorbidities and stroke severity indicators, a prolonged length of stay was more common for Black patients.

Researchers have identified new details about the link between certain cancer therapies and heart complications. Could their work lead to key improvements in patient care?